Safety of a Second Dose of Biken's Varicella Vaccine
This study has been completed.
Sponsor:
Sanofi
Information provided by:
Sanofi
ClinicalTrials.gov Identifier:
NCT00830648
First received: January 27, 2009
Last updated: April 8, 2010
Last verified: April 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of the present study is to assess and document the safety of a second dose of Varicella Biken vaccine administered at 4 to 6 years of age in healthy children having previously received a first dose of Varicella Biken vaccine.
All subjects will receive a second dose of Varicella vaccine (Varicella Biken) at 4 to 6 years of age.
The expected total duration of follow-up (first visit to last visit) for each subject will be one month.
| Condition | Intervention | Phase |
|---|---|---|
|
Varicella |
Biological: Live Attenuated Varicella Virus Vaccine |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Safety of a Second Dose of Biken's Varicella Vaccine Administered at 4 to 6 Years of Age in Healthy Children in Argentina |
Resource links provided by NLM:
Further study details as provided by Sanofi:
Primary Outcome Measures:
- To provide information concerning the safety after administration of Varicella vaccine [ Time Frame: one month after vaccination ] [ Designated as safety issue: Yes ]
| Enrollment: | 122 |
| Study Start Date: | January 2009 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 |
Biological: Live Attenuated Varicella Virus Vaccine
0.5 mL, Subcutaneous
Other Name: Varicela Biken
|
Eligibility| Ages Eligible for Study: | 4 Years to 6 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria :
- Aged 4 to 6 years on the day of inclusion.
- Informed consent form signed by the parent(s) or legal guardian and by an independent witness.
- Subject and parent/guardian able to attend all scheduled visits and comply with all trial procedures.
- Written documentation of receipt of a first dose of Varicella Biken vaccine more than 3 months before inclusion.
Exclusion Criteria:
- Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the trial vaccination.
- Planned participation in another clinical trial during the present trial period.
- Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy.
- Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances.
- Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the investigator.
- Receipt of any vaccine in the 4 weeks preceding the trial vaccination;
- Planned receipt of any vaccine in the 4 weeks following the trial vaccination.
- Known Human Immunodeficiency Virus (HIV), HBs antigen, or Hepatitis C seropositivity.
- History of varicella infection (confirmed either clinically, serologically or microbiologically).
- Previous vaccination against varicella disease with a vaccine different from Varicella Biken vaccine.
- Febrile illness (temperature ≥ 37.5°C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment.
Contacts and Locations
More Information
Additional Information:
Related Info 
Related Info 
No publications provided
| Responsible Party: | Medical Director, Sanofi Pasteur SA |
| ClinicalTrials.gov Identifier: | NCT00830648 History of Changes |
| Other Study ID Numbers: | VBK12 |
| Study First Received: | January 27, 2009 |
| Last Updated: | April 8, 2010 |
| Health Authority: | Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica |
Keywords provided by Sanofi:
|
varicella-zoster virus varicella |
Additional relevant MeSH terms:
|
Chickenpox Herpes Zoster Herpesviridae Infections DNA Virus Infections Virus Diseases |
ClinicalTrials.gov processed this record on May 22, 2013